Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mantle cell lymphoma
Biotech
BeOne asset hits primary endpoint, tees up blood cancer filings
The trial of sonrotoclax hit its primary endpoint, furthering BeOne’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma.
Nick Paul Taylor
Aug 29, 2025 9:50am
Facing a crowded market for BTK inhibitors, Oncternal bows out
Apr 4, 2023 4:00am
AbbVie pens Imbruvica pact to support pivotal Oncternal trial
Jul 15, 2022 9:55am
BioNova adds to blood cancer portfolio with $200M Sutro deal
Oct 12, 2021 10:49am
Gilead's Kite files for FDA approval of second CAR-T therapy
Dec 12, 2019 8:25am
Lilly plots 'ambitious' cancer program after sharing early data
Dec 8, 2019 4:30pm
